Kindred Healthcare (KND) Lifted to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Kindred Healthcare (NYSE:KND) from a hold rating to a buy rating in a research report report published on Wednesday morning. They currently have $11.00 price target on the health services provider’s stock.

According to Zacks, “Kindred Healthcare, Inc., a top-105 private employer in the United States, is a FORTUNE 500 healthcare services company based in Louisville, Kentucky with annual revenues of approximately $6.1 billion(1). Kindred’s continuing operations, through its subsidiaries, had approximately 86,400 employees providing healthcare services in 2,475 locations in 45 states, including 77 long-term acute care hospitals, 19 inpatient rehabilitation hospitals, 16 sub-acute units, 609 Kindred at Home home health, hospice and non-medical home care sites of service, 101 inpatient rehabilitation units (hospital-based) and contract rehabilitation service businesses which served 1,653 non-affiliated sites of service. Ranked as one of Fortune magazine’s Most Admired Healthcare Companies for eight years, Kindred’s mission is to promote healing, provide hope, preserve dignity and produce value for each patient, resident, family member, customer, employee and shareholder they serve. “

Several other research firms have also issued reports on KND. ValuEngine upgraded Kindred Healthcare from a sell rating to a hold rating in a research report on Thursday, November 9th. Stifel Nicolaus upgraded Kindred Healthcare from a sell rating to a hold rating and set a $7.00 target price for the company in a research report on Monday, November 20th. Bank of America decreased their target price on Kindred Healthcare from $7.50 to $6.50 and set an underperform rating for the company in a research report on Thursday, September 21st. Deutsche Bank reiterated a hold rating and issued a $9.00 price objective (down from $10.00) on shares of Kindred Healthcare in a research report on Monday, September 18th. Finally, Mizuho reiterated a neutral rating and issued a $7.50 price objective (down from $8.00) on shares of Kindred Healthcare in a research report on Tuesday, October 10th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $9.31.

Kindred Healthcare (KND) remained flat at $$9.25 during trading on Wednesday. The stock had a trading volume of 532,985 shares, compared to its average volume of 2,701,676. The company has a market capitalization of $846.07, a price-to-earnings ratio of 46.25 and a beta of 1.20. Kindred Healthcare has a 12 month low of $5.50 and a 12 month high of $11.90. The company has a debt-to-equity ratio of 6.22, a quick ratio of 1.53 and a current ratio of 1.55.

Kindred Healthcare (NYSE:KND) last posted its earnings results on Monday, November 6th. The health services provider reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.08. The company had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.44 billion. Kindred Healthcare had a positive return on equity of 2.29% and a negative net margin of 8.06%. The company’s revenue for the quarter was down 5.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.05 EPS. sell-side analysts anticipate that Kindred Healthcare will post 0.31 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of KND. Schwab Charles Investment Management Inc. lifted its stake in Kindred Healthcare by 23.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,129,938 shares of the health services provider’s stock valued at $13,164,000 after acquiring an additional 217,196 shares in the last quarter. Rhumbline Advisers lifted its stake in Kindred Healthcare by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 178,931 shares of the health services provider’s stock valued at $2,085,000 after acquiring an additional 449 shares in the last quarter. SG Americas Securities LLC lifted its stake in Kindred Healthcare by 35.8% in the 2nd quarter. SG Americas Securities LLC now owns 28,396 shares of the health services provider’s stock valued at $331,000 after acquiring an additional 7,481 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Kindred Healthcare by 2.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,488,869 shares of the health services provider’s stock valued at $17,345,000 after acquiring an additional 34,553 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Kindred Healthcare by 0.9% in the 2nd quarter. Legal & General Group Plc now owns 355,649 shares of the health services provider’s stock valued at $4,143,000 after acquiring an additional 3,018 shares in the last quarter. Institutional investors and hedge funds own 85.16% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/14/kindred-healthcare-knd-lifted-to-buy-at-zacks-investment-research.html.

About Kindred Healthcare

Kindred Healthcare, Inc, incorporated on March 27, 1998, is a healthcare services company. The Company, through its subsidiaries, operates transitional care (TC) hospitals, a home health, hospice and community care business, inpatient rehabilitation hospitals (IRFs), a contract rehabilitation services business, nursing centers and assisted living facilities across the United States.

Get a free copy of the Zacks research report on Kindred Healthcare (KND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kindred Healthcare (NYSE:KND)

Receive News & Ratings for Kindred Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply